Oncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044

Oncolytics Biotech ( (ONCY) ) has issued an announcement.

Oncolytics Biotech has outlined an expanded intellectual property strategy for its lead immunotherapy candidate pelareorep, centered on new and planned patent filings designed to extend its commercial life well into the 2040s. The company has submitted a Track 1 prioritized manufacturing patent application to the U.S. Patent and Trademark Office that, if granted, could protect pelareorep-related manufacturing innovations until 2044, and it expects a final decision on this application in the third quarter of 2026. Oncolytics also plans to file additional patents covering both manufacturing processes and novel therapeutic uses that could push IP protection beyond 2044, bolstering its ability to support late-stage clinical development, future regulatory approvals and eventual commercialization. Management underscores that reinforcing the IP runway around pelareorep is a central plank in its long-term value creation strategy, aiming to secure returns for shareholders while safeguarding innovation as the drug shows encouraging activity in gastrointestinal cancers and other difficult-to-treat tumor types.

The most recent analyst rating on (ONCY) stock is a Hold with a $0.87 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is driven primarily by weak financial performance (no revenue, large losses, heavy cash burn) and heightened balance-sheet strain from sharply reduced equity. Technical indicators also point to a weak trend and bearish momentum. Valuation provides only limited support because the negative P/E reflects ongoing losses and there is no dividend yield provided.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent aimed at turning immunologically ‘cold’ tumors ‘hot’ by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors primarily in metastatic pancreatic and breast cancers, both of which have received FDA Fast Track designation, as well as other gastrointestinal tumors, and is actively seeking strategic partnerships to accelerate development and commercial impact.

Average Trading Volume: 740,012

Technical Sentiment Signal: Sell

Current Market Cap: $103.8M

For detailed information about ONCY stock, go to TipRanks’ Stock Analysis page.